Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of membrane lipid metabolic process. [GO_REF:0000058, GOC:TermGenie, PMID:25954280]
Regulation of membrane lipid metabolic process is a complex and tightly controlled process that ensures the proper composition and function of cellular membranes. Membranes are essential for numerous cellular processes, including signaling, transport, and compartmentalization. To maintain membrane integrity and functionality, cells must precisely regulate the synthesis, modification, and degradation of membrane lipids.
**1. Transcriptional Regulation:**
- Transcription factors, such as sterol regulatory element-binding protein (SREBP) and peroxisome proliferator-activated receptors (PPARs), play crucial roles in controlling the expression of genes involved in lipid metabolism.
- SREBPs are activated in response to low sterol levels and stimulate the transcription of genes involved in cholesterol biosynthesis, uptake, and esterification.
- PPARs are activated by fatty acids and regulate the expression of genes involved in fatty acid oxidation, transport, and storage.
**2. Enzyme Regulation:**
- The activity of key enzymes involved in lipid metabolism is regulated by a variety of mechanisms, including:
- **Feedback Inhibition:** Products of metabolic pathways can inhibit the activity of enzymes involved in their synthesis.
- **Allosteric Regulation:** Regulatory molecules bind to enzymes at sites other than the active site, altering their activity.
- **Covalent Modification:** Phosphorylation, acetylation, and other post-translational modifications can alter enzyme activity.
- **Subcellular Localization:** The localization of enzymes within cells can influence their activity.
**3. Membrane Trafficking:**
- The movement of lipids between different cellular compartments is essential for proper membrane lipid metabolism.
- Vesicular transport and protein-mediated transport systems facilitate the delivery of lipids to specific membrane sites.
- Lipid chaperones assist in the transport and assembly of lipids within membranes.
**4. Lipolytic Pathways:**
- The breakdown of lipids is regulated by lipases, enzymes that hydrolyze ester bonds in lipids.
- Lipases are regulated by hormones, such as insulin and glucagon, and by the availability of substrates.
**5. Feedback Mechanisms:**
- Cells monitor the levels of membrane lipids and adjust their metabolic processes accordingly.
- Membrane lipid composition is constantly monitored and adjusted to maintain membrane fluidity, permeability, and signaling capabilities.
**6. Environmental Factors:**
- External factors, such as diet and stress, can influence membrane lipid metabolism.
- Dietary lipids can alter the levels of specific lipids in membranes.
- Stress can trigger changes in membrane lipid composition, including increased synthesis of stress-responsive lipids.
In summary, regulation of membrane lipid metabolic process involves a complex interplay of transcriptional, enzymatic, and trafficking mechanisms, as well as feedback loops and environmental influences. These intricate processes ensure the precise control of membrane lipid composition, crucial for maintaining cellular integrity, function, and adaptability.'
"
Protein | Definition | Taxonomy |
---|---|---|
Tumor necrosis factor receptor superfamily member 1A | A tumor necrosis factor receptor superfamily member 1A that is encoded in the genome of human. [PRO:WCB, UniProtKB:P19438] | Homo sapiens (human) |
Tumor necrosis factor | A tumor necrosis factor that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
way 151693 | |||
pentoxifylline | oxopurine | ||
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases. | methoxybenzenes | |
rolipram | pyrrolidin-2-ones | antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | |
sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
ganoderic acid a | triterpenoid | ||
ganoderiol f | ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source | triterpenoid | |
1-(phenylmethyl)benzimidazole | benzimidazoles | ||
chalcone | trans-chalcone : The trans-isomer of chalcone. | chalcone | EC 3.2.1.1 (alpha-amylase) inhibitor |
4'-methoxychalcone | 4'-methoxychalcone: RN given refers to compound with no isomeric designation | chalcones | |
luteolin-7-glucoside | luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum | beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone | antioxidant; plant metabolite |
apigetrin | apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. apigetrin: structure given in first source | beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative | antibacterial agent; metabolite; non-steroidal anti-inflammatory drug |
calycosin-7-o-beta-d-glucopyranoside | calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage. calycosin-7-O-beta-D-glucoside: from Radix Astragali | 4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative | |
spd-304 | SPD-304: structure in first source | ||
metochalcone | metochalcone: structure | ||
ganoderic acid f | ganoderic acid F: isolated from Ganoderma lucidum; structure in first source | triterpenoid | |
ganoderic acid c2 | ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source | triterpenoid |